BioTuesdays

Category - Feature

Feature

rEVO Biologics spearheading preeclampsia treatment

By Len Zehr Closely held rEVO Biologics is enrolling patients in a Phase 3 clinical trial of its ATryn recombinant human antithrombin for the treatment of early-onset preeclampsia, with top-line data expected in the...

November 11, 2014
Feature

CytoTools awaiting India clearance for DermaPro

By Len Zehr CytoTools AG (DE000A0KFRJ1/T5O) of Germany and its Indian marketing partner, Centaur Pharmaceuticals, expect to receive regulatory clearance in the current quarter in India for lead product, DermaPro, to...

November 4, 2014
Feature

AD focus shifts to treating agitation/aggression

By Len Zehr After years of fruitless search for new therapies to slow the deadly progression of Alzheimer’s disease (AD), researchers are having more success with experimental treatments for the neuropsychiatric...

October 28, 2014
Feature

In conversation with Ron Babecoff

By Len Zehr As a co-founder of BiondVax Pharmaceuticals (TASE:BNDX), Ron Babecoff has led the Israeli developer of a universal flu vaccine since its inception in 2003. Prior to BiondVax, Dr. Babecoff was with Omrix...

October 14, 2014
Feature

How Itamar Medical’s PAT signal is improving health

By Len Zehr Using an unique and innovative technology known as peripheral arterial tone (PAT), Itamar Medical (TASE:ITMR) is detecting the functioning and health of arteries through a finger sensor for the diagnosis of...

October 7, 2014
Feature

In conversation with Pivotal Therapeutics

By Len Zehr BioTuesdays.com recently sat down with the management team at Pivotal Therapeutics (OTCQX:PVTTF; CSE:PVO) to discuss the company’s VASCAZEN product that addresses Omega-3 deficiency in cardiovascular disease...

September 30, 2014